If there is one thing that I have learned when it comes to nonrevenue biotech investing over the last 3 years is that read-out of positive topline data is absolutely no guarantee for an SP jump. Anything related to a future of cash influx into the biotech (royalties deal, the buying in of big pharma, license deal, approval! etc) is. Look at NWBO. They reported positive topline data meeting all endpoints in an incredibly difficult trial for the orphan disease GBM, yet the SP declined! I have been laughed at, warning this may happen but the MB members were insisting the SP would increase to 4,5 even $20, and here it sits at 83 cents
Lesson is. Follow the potential influx of cash first and second the medical development of the drug in progress.
Market Data 
Markets 
